Literature DB >> 16371922

Low-dose radiation plus rapamycin promotes long-term bone marrow chimerism.

Jonathan D Powell1, Courtney Fitzhugh, Elizabeth M Kang, Mathew Hsieh, Ronald H Schwartz, John F Tisdale.   

Abstract

BACKGROUND: The ability to achieve significant donor engraftment without fully myeloablative conditioning has revolutionized allogeneic stem cell transplantation. These nonmyeloablative approaches may allow extension of this potentially curative modality to an increasing number of patients including those with non-malignant diseases. Although a number of regimens have been explored, the optimal means of conditioning has not been determined.
METHODS: We previously demonstrated that rapamycin (RAPA) has the ability to promote T-cell tolerance even in the presence of costimulation. In the current study, we examine the ability of rapamycin or the calcineurin inhibitor cyclosporine A (CSA) to promote chimerism in a murine haploidentical bone marrow transplantation model. Mice were conditioned with 300 cGy and received either RAPA at 3 mg/kg/day IP, CSA at 20 mg/kg/day IP, or no immunosuppression starting on the day before the transplant and continued for 4 weeks.
RESULTS: There was no apparent toxicity, and animals maintained normal blood counts throughout. More importantly, long-term macrochimerism was observed only in the RAPA-treated group.
CONCLUSIONS: These results establish a simple, nontoxic, irradiation-based regimen that facilitates engraftment without ablation. This strategy may prove useful in nonmalignant disorders such as hemoglobinopathies in which moderate levels of donor chimerism could prove curative.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16371922     DOI: 10.1097/01.tp.0000185299.72295.90

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  20 in total

1.  The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment.

Authors:  Greg M Delgoffe; Thomas P Kole; Yan Zheng; Paul E Zarek; Krystal L Matthews; Bo Xiao; Paul F Worley; Sara C Kozma; Jonathan D Powell
Journal:  Immunity       Date:  2009-06-19       Impact factor: 31.745

2.  Is human cell therapy research caught in a mousetrap?

Authors:  A John Barrett; J Joseph Melenhorst
Journal:  Mol Ther       Date:  2011-02       Impact factor: 11.454

3.  Allogeneic Reduced-Intensity Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease: a Single-Center Prospective Trial.

Authors:  Mark Parta; Corin Kelly; Nana Kwatemaa; Narda Theobald; Diane Hilligoss; Jing Qin; Douglas B Kuhns; Christa Zerbe; Steven M Holland; Harry Malech; Elizabeth M Kang
Journal:  J Clin Immunol       Date:  2017-07-28       Impact factor: 8.317

4.  Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT.

Authors:  Courtney D Fitzhugh; Matthew M Hsieh; Tiffani Taylor; Wynona Coles; Katherine Roskom; Delon Wilson; Elizabeth Wright; Neal Jeffries; Christopher J Gamper; Jonathan Powell; Leo Luznik; John F Tisdale
Journal:  Blood Adv       Date:  2017-04-19

5.  Pharmacologic modulation of niche accessibility via tyrosine kinase inhibition enhances marrow and thymic engraftment after hematopoietic stem cell transplantation.

Authors:  Natasha M Fewkes; Aviva C Krauss; Martin Guimond; Joanna L Meadors; Stefania Dobre; Crystal L Mackall
Journal:  Blood       Date:  2010-03-15       Impact factor: 22.113

Review 6.  Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now.

Authors:  Matthew M Hsieh; Courtney D Fitzhugh; John F Tisdale
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

7.  Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation.

Authors:  Zaid Al-Kadhimi; Zartash Gul; Roberto Rodriguez; Wei Chen; Daryn Smith; Alice Mitchell; Muneer Abidi; Lois Ayash; Abhinav Deol; Lawrence Lum; Stephen Forman; Voravit Ratanatharathorn; Joseph Uberti
Journal:  Biol Blood Marrow Transplant       Date:  2012-06-16       Impact factor: 5.742

8.  Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.

Authors:  Matthew M Hsieh; Elizabeth M Kang; Courtney D Fitzhugh; M Beth Link; Charles D Bolan; Roger Kurlander; Richard W Childs; Griffin P Rodgers; Jonathan D Powell; John F Tisdale
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

9.  Sirolimus and post transplant Cy synergistically maintain mixed chimerism in a mismatched murine model.

Authors:  C D Fitzhugh; R P Weitzel; M M Hsieh; O A Phang; C Madison; L Luznik; J D Powell; J F Tisdale
Journal:  Bone Marrow Transplant       Date:  2013-04-22       Impact factor: 5.483

10.  Busulfan produces efficient human cell engraftment in NOD/LtSz-Scid IL2Rgamma(null) mice.

Authors:  Jun Hayakawa; Matthew M Hsieh; Naoya Uchida; Oswald Phang; John F Tisdale
Journal:  Stem Cells       Date:  2009-01       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.